Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant347 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02032810 | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 |
| NCT04185220 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT00784108 | Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry. | completed | Phase 1 | 11 | University of California, IrvineOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04551352 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | completed | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 6 | Oct 3, 2022 | clinicaltrials |
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | terminated | Phase 1 | 2 | Codiak BioSciencesINDUSTRY | 1 | Sep 2, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT01445535 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02145130 | Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | completed | Phase 1 | 12 | University of ZurichOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04171791 | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 | 4 | Yale UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | completed | Phase 1 | 44 | Innate PharmaINDUSTRY | 4 | Jan 20, 2021 | clinicaltrials |
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 1 | 5 | Moleculin Biotech, Inc.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | terminated | Phase 1 | 5 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | terminated | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04274816 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | completed | Phase 1 | 13 | A.J.M. van den EertweghOTHER | 0 | Feb 18, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00554827 | Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 55 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT01134341 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 34 | Acrotech Biopharma Inc.INDUSTRY | 2 | Dec 18, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2023source: clinicaltrials